XL309
AssetAlso ISM3091
Inhibits USP1.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- USP1
- 1
- Indication
- 1
- Trial
- 2
- Developers
Indications
1BRCA-mutated cancer
Phase 1, Recruiting, NCT05932862, clinicaltrials.gov, 8 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners3
- Trials1
- Evidence for its targets1
- Competitors8
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 10 Oct 2026, 3 sources